Mesothelioma

Also known as: Mesotheliomas

DrugDrug NameDrug Description
DB00305MitomycinAn antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional alkylating agents causing cross-linking of DNA and inhibition of DNA synthesis. [PubChem]
DB00642PemetrexedPemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma as well as non-small cell lung cancer.
DrugDrug NamePhaseStatusCount
DB12845Amatuximab0Terminated1
DB00556Perflutren0Not Yet Recruiting1
DB11104Sulfur hexafluoride0Not Yet Recruiting1
DB03496Alvocidib1Terminated1
DB12845Amatuximab1Completed1
DB06616Bosutinib1Recruiting1
DB08875Cabozantinib1Recruiting1
DB09061Cannabidiol1Recruiting1
DB00515Cisplatin1Completed3
DB00515Cisplatin1Recruiting1
DB00531Cyclophosphamide1Recruiting1
DB01234Dexamethasone1Completed1
DB01248Docetaxel1Recruiting1
DB01590Everolimus1Recruiting1
DB00619Imatinib1Completed1
DB01229Paclitaxel1Recruiting1
DB06603Panobinostat1Completed1
DB09037Pembrolizumab1Recruiting1
DB00642Pemetrexed1Completed3
DB00642Pemetrexed1Recruiting2
DB00398Sorafenib1Completed1
DB00577Valaciclovir1Active Not Recruiting1
DB00041Aldesleukin1 / 2Recruiting1
DB00112Bevacizumab1 / 2Terminated1
DB00958Carboplatin1 / 2Terminated1
DB00531Cyclophosphamide1 / 2Active Not Recruiting1
DB12282Defactinib1 / 2Recruiting1
DB01073Fludarabine1 / 2Recruiting1
DB09037Pembrolizumab1 / 2Recruiting1
DB09037Pembrolizumab1 / 2Withdrawn1
DB00642Pemetrexed1 / 2Terminated1
DB00552Pentostatin1 / 2Active Not Recruiting1
DB06810Plicamycin1 / 2Recruiting1
DB05220Alisertib2Active Not Recruiting1
DB00112Bevacizumab2Completed3
DB00188Bortezomib2Unknown Status1
DB08870Brentuximab vedotin2Recruiting1
DB00958Carboplatin2Completed2
DB00515Cisplatin2Approved for Marketing1
DB00515Cisplatin2Completed2
DB00515Cisplatin2Recruiting2
DB00515Cisplatin2Terminated1
DB00515Cisplatin2Unknown Status1
DB01234Dexamethasone2Unknown Status1
DB11714Durvalumab2Recruiting2
DB00530Erlotinib2Completed1
DB00544Fluorouracil2Completed1
DB00317Gefitinib2Completed1
DB00441Gemcitabine2Completed2
DB00441Gemcitabine2Recruiting1
DB00441Gemcitabine2Unknown Status1
DB06186Ipilimumab2Active Not Recruiting1
DB00563Methotrexate2Recruiting1
DB12334Milataxel2Unknown Status1
DB01204Mitoxantrone2Completed1
DB11793Niraparib2Not Yet Recruiting1
DB09035Nivolumab2Active Not Recruiting1
DB00526Oxaliplatin2Unknown Status2
DB09037Pembrolizumab2Recruiting1
DB00642Pemetrexed2Approved for Marketing1
DB00642Pemetrexed2Completed5
DB00642Pemetrexed2Recruiting2
DB00642Pemetrexed2Terminated1
DB00642Pemetrexed2Unknown Status1
DB06810Plicamycin2Recruiting1
DB00398Sorafenib2Unknown Status1
DB12887Tazemetostat2Active Not Recruiting1
DB12887Tazemetostat2Recruiting1
DB11771Tremelimumab2Recruiting1
DB05294Vandetanib2Terminated1
DB00361Vinorelbine2Active Not Recruiting1
DB00361Vinorelbine2Terminated1
DB00361Vinorelbine2Unknown Status1
DB00399Zoledronic acid2Completed1
DB00515Cisplatin2 / 3Completed1
DB00515Cisplatin2 / 3Recruiting1
DB00642Pemetrexed2 / 3Completed1
DB00642Pemetrexed2 / 3Recruiting1
DB00958Carboplatin3Recruiting1
DB00515Cisplatin3Recruiting2
DB06186Ipilimumab3Recruiting1
DB09079Nintedanib3Recruiting1
DB09035Nivolumab3Recruiting2
DB00642Pemetrexed3Completed1
DB00642Pemetrexed3Recruiting2
DB02546Vorinostat3Completed1
DB06151AcetylcysteineNot AvailableUnknown Status1
DB01142DoxepinNot AvailableActive Not Recruiting1
DB08818Hyaluronic acidNot AvailableCompleted1
DB01362IohexolNot AvailableActive Not Recruiting1